All news

COR guidance cut on 2026 sales headwinds

Alpha Vantage · Morningstar · · AI-summarised by FinFlash

Pricing headwinds and industry trends are expected to cut into Cencora's 2026 sales, contributing to a guidance cut and stock selloff. The company remains one of the top three US pharmaceutical wholesalers, alongside Cardinal Health and McKesson, which together supply over 90% of the domestic market. Cencora's fundamental business strategy and outlook are described as strong.

Read original source

COR company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.